BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 927 filers reported holding BAXTER INTL INC in Q4 2016. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $447,000 | +4.4% | 5,800 | 0.0% | 0.05% | +4.2% |
| Q2 2018 | $428,000 | +13.5% | 5,800 | 0.0% | 0.05% | +14.3% |
| Q1 2018 | $377,000 | +0.5% | 5,800 | 0.0% | 0.04% | +2.4% |
| Q4 2017 | $375,000 | +3.0% | 5,800 | 0.0% | 0.04% | -2.4% |
| Q3 2017 | $364,000 | +3.7% | 5,800 | 0.0% | 0.04% | -12.5% |
| Q2 2017 | $351,000 | +16.6% | 5,800 | 0.0% | 0.05% | +33.3% |
| Q1 2017 | $301,000 | +17.1% | 5,800 | 0.0% | 0.04% | +12.5% |
| Q4 2016 | $257,000 | -6.9% | 5,800 | 0.0% | 0.03% | -11.1% |
| Q3 2016 | $276,000 | +3.4% | 5,800 | -1.9% | 0.04% | 0.0% |
| Q2 2016 | $267,000 | +10.3% | 5,911 | +0.2% | 0.04% | +5.9% |
| Q1 2016 | $242,000 | +15.2% | 5,900 | +7.3% | 0.03% | +13.3% |
| Q4 2015 | $210,000 | -45.5% | 5,500 | 0.0% | 0.03% | -42.3% |
| Q2 2015 | $385,000 | +2.1% | 5,500 | 0.0% | 0.05% | +2.0% |
| Q1 2015 | $377,000 | -3.3% | 5,500 | 0.0% | 0.05% | -5.6% |
| Q4 2014 | $390,000 | -1.3% | 5,500 | 0.0% | 0.05% | -5.3% |
| Q3 2014 | $395,000 | -0.8% | 5,500 | 0.0% | 0.06% | 0.0% |
| Q2 2014 | $398,000 | -6.8% | 5,500 | -5.2% | 0.06% | -23.0% |
| Q1 2014 | $427,000 | +6.0% | 5,800 | 0.0% | 0.07% | +4.2% |
| Q4 2013 | $403,000 | +5.8% | 5,800 | 0.0% | 0.07% | -5.3% |
| Q3 2013 | $381,000 | -3.5% | 5,800 | +1.8% | 0.08% | -13.8% |
| Q2 2013 | $395,000 | – | 5,700 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |